Search research articles
Contact Us
Filters
Showing results (161-170 of 186) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2025
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
O Metzger Filho, F Cardoso, C Poncet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M Ignatiadis, S Litière, F Rothe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2014
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
H S Rugo, K I Pritchard, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2016
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
S Michiels, L Pugliano, S Marguet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
M Piccart, G N Hortobagyi, M Campone, et al.
ESMO Open
|
January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
E de Azambuja, E Agostinetto, M Procter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
C Oakman, P A Francis, J Crown, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 186) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
January 26, 2025
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial
O Metzger Filho, F Cardoso, C Poncet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial
M Ignatiadis, S Litière, F Rothe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 12, 2014
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
H S Rugo, K I Pritchard, M Gnant, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial
W Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 11, 2016
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
S Michiels, L Pugliano, S Marguet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2014
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
M Piccart, G N Hortobagyi, M Campone, et al.
ESMO Open
|
January 21, 2023
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
E de Azambuja, E Agostinetto, M Procter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial
C Oakman, P A Francis, J Crown, et al.
Page
of 19